Motif Bio Presents Iclaprim Data at ESCMID/ASM Conference
September 05, 2018 02:00 ET
|
Motif BioSciences Inc.
Iclaprim overview presented in State of the Art LectureSafety analysis of diabetic patients in REVIVE ABSSSI trials shows fewer adverse events versus vancomycinSurveillance data confirm in vitro...
Motif Bio to Present Iclaprim Data at ESCMID/ASM Conference
August 17, 2018 02:00 ET
|
Motif BioSciences Inc.
NEW YORK, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim...
Motif Bio Announces FDA Acceptance of New Drug Application with Priority Review for Iclaprim for Treatment of Acute Bacterial Skin and Skin Structure Infections
August 14, 2018 02:00 ET
|
Motif BioSciences Inc.
NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the U.S....
Motif Bio to Present at Investor Events in August and September
August 09, 2018 02:00 ET
|
Motif BioSciences Inc.
NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the...
Motif Bio Announces Notice of Allowance for Two U.S. Iclaprim Patents with Expiration in 2037
August 08, 2018 02:00 ET
|
Motif BioSciences Inc.
NEW YORK, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB) ("Motif Bio" or the "Company"), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics,...
Motif Bio Announces Resignation of Robert Bertoldi from Board of Directors
July 03, 2018 02:00 ET
|
Motif BioSciences Inc.
NEW YORK, July 03, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that...
Result of Annual General Meeting
June 19, 2018 10:00 ET
|
Motif BioSciences Inc.
NEW YORK, June 19, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the...
Motif Bio Submits NDA for Iclaprim
June 14, 2018 02:00 ET
|
Motif BioSciences Inc.
NEW YORK, June 14, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced the...
Motif Bio Announces New Iclaprim Data Presented at ASM Microbe 2018
June 11, 2018 02:00 ET
|
Motif BioSciences Inc.
Pooled efficacy and safety data from REVIVE Phase 3 trials presentedData also published in peer-reviewed journal, International Journal of Antimicrobial Agents NEW YORK, June 11, 2018 (GLOBE...
Motif Bio to present at Jefferies Global Healthcare Conference in New York
May 31, 2018 02:00 ET
|
Motif BioSciences Inc.
NEW YORK, May 31, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the...